上市公司独立董事候选人声明与承诺 三、本人符合中国证监会《上市公司独立董事管理办法》 和深圳证券交易所业务规则规定的独立董事任职资格和条件。 ☑ 是 □ 否 声明人杨德杰作为拓新药业集团股份有限公司第五届董事会 独立董事候选人，已充分了解并同意由提名人拓新药业集团股份 有限公司董事会提名为拓新药业集团股份有限公司（以下简称该 公司）第五届董事会独立董事候选人。现公开声明和保证，本人 与该公司之间不存在任何影响本人独立性的关系，且符合相关法 律、行政法规、部门规章、规范性文件和深圳证券交易所业务规 则对独立董事候选人任职资格及独立性的要求，具体声明并承诺 如下事项： 一、本人已经通过拓新药业集团股份有限公司第五届董事会 提名委员会或者独立董事专门会议资格审查，提名人与本人不存 在利害关系或者其他可能影响独立履职情形的密切关系。 ☑ 是 □ 否 如否，请详细说明： 二、本人不存在《中华人民共和国公司法》第一百七十八 条等规定不得担任公司董事的情形。 ☑ 是 □ 否 如否，请详细说明： 如否，请详细说明： 四、本人符合该公司章程规定的独立董事任职条件。 ☑ 是 □ 否 如否，请详细说明： 五、本人已经参加培训并取得 ...

证券代码：301089 证券简称：拓新药业 公告编号：2025-052 3、会议召开的合法、合规性：召开本次会议的议案已于2025年10月28日经 公司第五届董事会第八次会议审议通过，本次会议的召集程序符合有关法律、法 规、规范性文件和《拓新药业集团股份有限公司章程》的规定。 4、会议召开的日期、时间 （1）现场会议时间：2025年11月13日（星期四）上午9:00 （2）网络投票时间：2025年11月13日（星期四） 2、股东会的召集人：公司董事会 拓新药业集团股份有限公司 关于召开2025年第二次临时股东会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 拓新药业集团股份有限公司（以下简称"公司"）第五届董事会第八次会议 审议通过了《关于提请召开2025年第二次临时股东会的议案》，决定于2025年11 月13日（星期四）上午9:00召开2025年第二次临时股东会。现将有关情况通知如 下： 一、召开会议的基本情况 1、股东会届次：2025年第二次临时股东会 其中，通过深圳证券交易所交易系统进行网络投票的时间为2025年11月13 日9:15-9:25， ...

证券代码：301089 证券简称：拓新药业 公告编号：2025-051 拓新药业集团股份有限公司 第五届董事会第八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或者重大遗漏。 一、董事会会议召开情况 拓新药业集团股份有限公司（以下简称"公司"）第五届董事会第八次会 议通知于 2025 年 10 月 18 日以电话、邮件等方式向各位董事发出，会议于 2025 年 10 月 28 日以现场会议结合通讯形式在公司会议室召开。本次会议由公 司董事长杨西宁先生召集并主持，应出席会议的董事 9 人，实际出席会议的董 事 9 人，其中以通讯形式出席会议的董事 4 人，分别为咸生林先生、杨邵华先 生、靳焱顺先生、刘建伟先生，公司高级管理人员列席了会议。 本次会议的召集、召开及表决符合《中华人民共和国公司法》及《拓新药 业集团股份有限公司章程》（以下简称《公司章程》）的有关规定，会议合法 有效。 二、董事会会议审议情况 1、审议通过《关于公司<2025 年第三季度报告>的议案》 经审议，董事会认为《2025年第三季度报告》切实反映了本报告期公司真 实情况，所记载事项不存在虚 ...

Core Viewpoint - The company reported a significant decline in both revenue and net profit for the third quarter and the first three quarters of the year, indicating financial challenges ahead [1] Financial Performance - The third quarter revenue was 89.65 million yuan, a decrease of 16.21% compared to the previous period [1] - The net profit for the third quarter was a loss of 11.88 million yuan, representing a drastic decline of 1,258.62% [1] - For the first three quarters, the total revenue was 272 million yuan, down 16.64% year-on-year [1] - The net profit for the first three quarters was a loss of 30.16 million yuan, reflecting a decline of 1,036.53% [1]

Financial Performance - The company's revenue for Q3 2025 was ¥89,653,837.13, representing a decrease of 16.21% compared to the same period last year[5] - The net profit attributable to shareholders was a loss of ¥11,880,527.36, a significant decline of 1,258.62% year-over-year[5] - The basic earnings per share for the period was -¥0.09, reflecting an 800.00% decrease compared to the previous year[5] - Total operating revenue for the current period was ¥271,553,589.37, a decrease of 16.6% from ¥325,753,716.96 in the previous period[22] - Net profit for the current period was a loss of ¥30,161,076.91, compared to a loss of ¥2,653,779.13 in the previous period[24] - Basic earnings per share for the current period was -¥0.24, compared to -¥0.02 in the previous period[24] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,689,365,161.72, down 3.92% from the end of the previous year[5] - The company's total current assets decreased from 677,012,163.72 CNY to 608,393,641.46 CNY, a reduction of approximately 10.14%[18] - The total assets decreased from 1,758,243,932.05 CNY to 1,689,365,161.72 CNY, a decline of about 3.92%[19] - The total liabilities decreased from 1,758,243,932.05 CNY to 1,689,365,161.72 CNY, indicating a reduction in financial obligations[19] - Total liabilities decreased to ¥167,006,178.19 from ¥205,723,871.61, reflecting a reduction of approximately 18.9%[20] - Total equity attributable to shareholders decreased to ¥1,522,358,983.53 from ¥1,552,520,060.44, a decline of about 1.9%[20] Cash Flow - The company reported a cash flow deficit from operating activities of ¥22,789,583.38, a decline of 120.88% year-to-date[5] - Cash flow from operating activities showed a net outflow of ¥22,789,583.38, a significant decline from a net inflow of ¥109,128,879.30 in the previous period[26] - Cash inflow from investment activities increased to ¥728,911,595.04, up from ¥463,146,798.09 in the previous period[26] - Cash flow from financing activities showed a net outflow of $1,224,188.16, compared to a larger outflow of $31,544,611.85 in the previous period, indicating a reduction in financing costs[27] - The net increase in cash and cash equivalents was $172,158.76, contrasting sharply with a substantial increase of $63,558,641.67 in the prior period[27] - The ending balance of cash and cash equivalents stood at $61,953,892.01, down from $194,291,924.17 in the previous period, reflecting a decrease of approximately 68.1%[27] Shareholder Information - Total number of common stock shareholders at the end of the reporting period is 18,134[12] - The largest shareholder, Yang Xining, holds 27.23% of shares, totaling 34,455,650 shares[12] Operational Metrics - The company experienced a 35.32% decrease in accounts receivable financing, primarily due to a reduction in outstanding receivables[9] - The company's other income decreased by 58.18% to ¥4,559,553.75, primarily due to a reduction in government subsidies received[9] - The company reported a significant increase in contract liabilities by 226.70% to ¥2,968,011.02, mainly due to an increase in advance payments received[9] - The company's fixed assets increased by 64.20% to ¥816,687,624.08, attributed to the transfer of construction projects to fixed assets[9] - The inventory increased from 178,882,618.60 CNY to 190,791,788.13 CNY, an increase of approximately 6.14%[18] - The total non-current assets remained relatively stable, decreasing slightly from 1,081,231,768.33 CNY to 1,080,971,520.26 CNY[19] Research and Development - Research and development expenses increased to ¥31,165,593.91, up from ¥28,913,083.62, indicating a focus on innovation[23] Tax and Audit Information - The company reported a significant increase in deferred income tax liabilities, which rose to ¥3,422,861.69 from ¥4,210,778.32, indicating potential future tax obligations[20] - The company did not undergo an audit for the third quarter financial report, which may impact investor confidence[28]

证券代码：301089 证券简称：拓新药业 公告编号：2025-055 拓新药业集团股份有限公司 关于对外投资设立子公司 拓新药业（内蒙古）有限公司的公告 二、交易对方的基本情况 本次对外投资除本公司以外无其他投资主体。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或者重大遗漏。 一、对外投资概述 拓新药业集团股份有限公司(以下简称"公司")于 2025 年 10 月 28 日召开 的第五届董事会第八次会议审议通过了《关于对外投资设立子公司的议案》。根 据《深圳证券交易所创业板股票上市规则》《公司章程》等相关规定，本次对外 投资事项在公司董事会决策权限范围内，无需提交公司股东大会审议。 本次对外投资事项不构成关联交易，也不构成《上市公司重大资产重组管理 办法》规定的重大资产重组。 销售（依法须经批准的项目，经相关部门批准后方可开展经营活动）。 三 、投资标的的基本情况 1 上述信息以工商部门最终核准登记的内容为准。 四、对外投资合同的主要内容 本次对外投资为公司设立全资子公司，无须签署对外投资合同。 五、对外投资的目的、存在的风险和对公司的影响 1、对外投资的目的 1、 ...

Core Viewpoint - The company has approved the establishment of a wholly-owned subsidiary in Hohhot, Inner Mongolia, focusing on the research, production, and sales of fermentation-related products [1] Group 1 - The company will set up a wholly-owned subsidiary named "Tuo Xin Pharmaceutical (Inner Mongolia) Co., Ltd." with a registered capital of 50 million yuan [1] - The investment for this subsidiary will be fully funded by the company's own or self-raised funds [1] - The company will hold 100% equity in the new subsidiary [1]

Core Insights - On October 24, 2023, TuoXin Pharmaceutical executed a block trade of 1.3 million shares, amounting to 33.228 million yuan, which represented 30.07% of the total trading volume for the day [1][2] - The transaction price was 25.56 yuan per share, reflecting an 18.57% discount compared to the market closing price of 31.39 yuan [1][2] Summary by Category Trading Activity - The block trade involved 1.3 million shares of TuoXin Pharmaceutical [1][2] - The total transaction value was 33.228 million yuan [1][2] Price Analysis - The executed price of the shares was 25.56 yuan, which is significantly lower than the market closing price [1][2] - The discount of 18.57% indicates a notable deviation from the market valuation [1][2]

Core Viewpoint - TuoXin Pharmaceutical reported that as of October 20, 2025, the number of shareholders is 18,067 [2] Summary by Category - **Company Information** - TuoXin Pharmaceutical has 18,067 shareholders as of the specified date [2] - **Investor Engagement** - The company responded to investor inquiries on an interactive platform regarding shareholder numbers [2]

Core Viewpoint - The company, Tuoxin Pharmaceutical, announced that its wholly-owned subsidiary, Xinxiang Jingquan Biotechnology Co., Ltd., has successfully obtained Self-GRAS status for its product, Glyceryl Phosphoryl Choline, following a rigorous scientific evaluation in accordance with the FDA's Generally Recognized as Safe (GRAS) criteria [1] Group 1 - The product Glyceryl Phosphoryl Choline has completed a strict scientific evaluation [1] - The Self-GRAS status indicates that the product is recognized as safe for its intended use [1] - This achievement may enhance the company's market position and product credibility in the pharmaceutical industry [1]